Abiopharma

🔍 Vautrinot Suzanne M (Director)

Company: WELLS FARGO & COMPANY/MN (WFC)

Report Date: 2026-04-28

Detailed Transactions and Holdings:

• Holds 0 shares of Common Stock, $1 2/3 Par Value (Direct)
  Date: 2026-04-28 | Code: H | shares_owned_after: 5,508.39 | Footnotes: F1
• Holds 0 shares of Common Stock, $1 2/3 Par Value (Direct)
  Date: 2026-04-28 | Code: H | nature_of_ownership: Through Trust | shares_owned_after: 12,129.00
• Acquired 3,436 shares of Common Stock Units (Derivative)
  Date: 2026-04-28 | Code: A | equity_swap_involved: 0 | shares_owned_after: 17,851.96 | transaction_form_type: 4 | Footnotes: F2, F3, F2, F2, F4

Footnotes:

• F1: Includes shares acquired under a dividend reinvestment program since the reporting person's most recent filing on Form 4.
• F2: Common Stock Units vested upon grant with settlement deferred until the later of termination of service as a director of Wells Fargo & Company (the "Company") or such later settlement date elected by the director.
• F3: Each Common Stock Unit represents a right to receive one share of Company common stock.
• F4: Includes dividend equivalents reinvested in additional Common Stock Units.
• REMARKS: Exhibit 24 - Power of Attorney